Tag Archives: Healthcare

TissueTech Inc. Awarded Four Patents for Proprietary Technology to Use Placental Tissue for Regenerative Medicine

Company has more than 40 issued patents

MIAMI – September 14, 2017 – TissueTech Inc. announced today that it has been awarded four patents by the U.S. Patent Trademark Office. Two of the patents cover methods of promoting bone formation and the others cover methods for lyophilizing and sterilizing placental tissue.

“TissueTech continues to maintain its status as the leader in the scientific understanding and innovative application of placental tissue in regenerative medicine,” said Amy Tseng, Chief Executive Officer of TissueTech. “In addition to being the recipient of four new patents, the company recently surpassed the milestone of 300,000 human implants performed by clinicians and our research is backed by more than 30 years of continuous funding through the National Institute of Health. The recognition of this technology and its use in medicine underscores our success in finding new and important arenas where regenerative therapy offers the potential to address underserved and unmet clinical needs and improve patients’ lives.”

The four patents issued to TissueTech apply to:

  • The use of placental tissue in different forms to address the typical effects of bone diseases including arthritis, osteoporosis, bone tumors, Paget’s Disease, and alveolar bone degradation.
  • A method of promoting or inducing osteogenesis in an individual in need thereof, comprising contacting a bone or joint in the individual with a therapeutically-effective amount of placental tissue.
  • The preservation and sterilization of placental tissue necessary to make it available to physicians for transplantation to patients in clinical need.
  • A method of preparing a placental tissue powder product by lyophilizing placental tissue and grinding the lyophilized tissue to generate a product that can be delivered less invasively.

”TissueTech was the first company to introduce cryopreserved umbilical cord and amniotic membrane tissues for clinical transplantation,” said Scheffer Tseng, MD, Ph.D., Chief Technology Officer of TissueTech. “As a pioneer in this space and with the continued support of our NIH grant and the private capital that we have raised, we will continue to lead in the development of innovative technologies and delivery techniques to better serve patients across all sectors of healthcare with regenerative therapy options.”

Numerous disease states are the direct result of damage to normal tissue and the associated inflammation, along with the body’s consequent inability to restore a normal state of function. Research has demonstrated that regenerative healing occurs in the fetal environment due to the inherent ability of the placental tissues, particularly the umbilical cord and amniotic membrane, to modulate inflammation and create an environment that is conducive to healing. More importantly, these properties can be preserved and transplanted to other environments to facilitate the improved outcomes following surgical procedures or even the closure of chronic, hard-to-heal wounds.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical markets products for use in the musculoskeletal and wound care markets; Bio-Tissue markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.

###

 

 

Amniox Medical Enters into Agreement with Intalere

ATLANTA, GA – June 8, 2017 – AMNIOX Medical, Inc., a TissueTech, Inc. company has announced an agreement with Intalere, to serve their members with its market leading human tissue allograft technology composed of both umbilical cord and amniotic membrane for wound healing and soft-tissue repair. Intalere is a professional supply chain company offering a comprehensive suite of services to empower healthcare providers to better manage their entire spend and ultimately deliver superior care.

The agreement includes NEOX® and CLARIX® CORD 1K®, 100 and FLO, and NEOX CORD RT in the Intalere advanced wound care-bioactive category. Preferred pricing for Intalere members extends to 3,651 acute care hospitals, 174 hospital-based physicians and 3,680 ambulatory surgery centers.

“This is a welcome partnership with an organization that prides itself on its ability to empower providers to serve their communities well, and serve them in a sustainable manner with the best medicine,” said Amniox Medical CEO Tom Dugan. “Intalere’s membership includes more than 65% of US hospitals and numerous ambulatory surgery centers, clinics and physician offices. In addition to expanding our presence around the country, this partnership highlights Amniox’s expanding leadership in providing regenerative medicine products that meet clinical needs effectively and deliver value.”

Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane. The biological components of these tissues have demonstrated regenerative properties that can provide healing benefits to patients with numerous medical conditions. In utero, wound healing occurs rapidly and with minimal scar, and this restorative ability is innate to placental tissues, including umbilical cord and amniotic membrane. Amniox utilizes its proprietary CryoTek® process, a cryopreservation technology, to preserve the biological and structural integrity of the native tissue which published studies have demonstrated preserves the HC-HA/PTX3 matrix that is key to the regenerative process.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue focuses on products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. Visit http://tissuetech.com to learn more.

About Intalere

Intalere’s mission focuses on elevating the operational health of America’s healthcare providers by designing tailored, smart solutions that deliver optimal cost, quality and clinical outcomes. We strive to be the essential partner for operational excellence in healthcare through customized solutions that address customers’ individual needs. We assist our customers in managing their entire spend, providing innovative technologies, products and services, and leveraging the best practices of a provider-led model. As Intalere draws on the power of our owner Intermountain Healthcare’s nationally-recognized supply chain expertise and leadership in technology, process improvement, and evidence-based clinical and business best practices, we are uniquely positioned to be the innovation leader in the healthcare industry. Visit http://www.intalere.com to learn more.

###